Xilio Therapeutics, Inc. (XLO)

Market Cap	36.27M
Revenue (ttm)	15.00M
Net Income (ttm)	-56.22M
Shares Out	51.83M
EPS (ttm)	-1.08
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	413,031
Open	0.7101
Previous Close	0.7180
Day's Range	0.6823 - 0.7180
52-Week Range	0.6150 - 1.7000
Beta	-0.11
Analysts	Buy
Price Target	3.00 (+328.69%)
Earnings Date	Nov 6, 2025

About XLO

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineere...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 22, 2021
• Employees: 64
• Stock Exchange: NASDAQ
• Ticker Symbol: XLO
• Website: https://xiliotx.com

Analyst Summary

According to 2 analysts, the average rating for XLO stock is "Buy." The 12-month stock price target is $3.0, which is an increase of 328.69% from the latest price.

Price Target

$3.0

(328.69% upside)

Analyst Consensus: Buy